Severe Nocturnal Hypoxemia, Not Just Obstructive Sleep Apnea, Predicts Reduced Survival in Non-Small Cell Lung Cancer Patients
Posted innews Oncology Respiratory

Severe Nocturnal Hypoxemia, Not Just Obstructive Sleep Apnea, Predicts Reduced Survival in Non-Small Cell Lung Cancer Patients

The NEOSAS-GFPC study demonstrates that severe sleep-related hypoxemia is an independent predictor of increased mortality in NSCLC patients, highlighting the clinical importance of monitoring nocturnal oxygen saturation beyond traditional apnea indices to improve prognostic accuracy and patient care.
Savolitinib Plus Osimertinib Redefines Second-Line Therapy for MET-Amplified, EGFR-Mutant NSCLC: Insights from the Phase 3 SACHI Trial
Posted innews Oncology

Savolitinib Plus Osimertinib Redefines Second-Line Therapy for MET-Amplified, EGFR-Mutant NSCLC: Insights from the Phase 3 SACHI Trial

The Phase 3 SACHI trial demonstrates that the combination of savolitinib and osimertinib significantly extends progression-free survival compared to chemotherapy in patients with MET-amplified, EGFR-mutated non-small-cell lung cancer who progressed on prior TKI therapy, offering a potent oral treatment alternative.
Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade
Posted innews Oncology Respiratory

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual checkpoint inhibition as a potent chemotherapy-free neoadjuvant alternative.
Tumor Treating Fields Significantly Delay Intracranial Progression in NSCLC Patients Following Stereotactic Radiosurgery: Results of the METIS Trial
Posted innews Oncology Radiology

Tumor Treating Fields Significantly Delay Intracranial Progression in NSCLC Patients Following Stereotactic Radiosurgery: Results of the METIS Trial

The Phase 3 METIS trial demonstrates that Tumor Treating Fields (TTFields) following stereotactic radiosurgery significantly prolongs time to intracranial progression in NSCLC patients with brain metastases, without compromising neurocognitive function or quality of life, offering a promising new treatment paradigm.
Bevacizumab and Fractionated Stereotactic Radiotherapy: A Synergistic Breakthrough for Extensive Brain Metastases in NSCLC
Posted innews Oncology Radiology

Bevacizumab and Fractionated Stereotactic Radiotherapy: A Synergistic Breakthrough for Extensive Brain Metastases in NSCLC

The GASTO-1053 phase II study demonstrates that combining bevacizumab with fractionated stereotactic radiotherapy significantly improves intracranial progression-free survival (18.3 months) and quality of life for NSCLC patients with extensive brain metastases, providing a safe, effective alternative to whole-brain radiotherapy.
SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset
Posted innews Oncology Respiratory

SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset

Two contemporary series show that SMARCA4‑altered NSCLC is molecularly and clinically heterogeneous: squamous tumors have high pathologic responses to neoadjuvant immunochemotherapy, while non‑squamous tumors—especially those with co‑occurring KRAS and STK11/KEAP1 alterations—are immune‑cold and have poor outcomes despite chemoimmunotherapy.
AI-Derived Body Composition Analysis Unveils Muscle Volume, Metformin-Associated Adipose Effects, and the Obesity Paradox in NSCLC: Clinical and Molecular Insights
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news

AI-Derived Body Composition Analysis Unveils Muscle Volume, Metformin-Associated Adipose Effects, and the Obesity Paradox in NSCLC: Clinical and Molecular Insights

AI-driven analysis identifies muscle volume as a robust predictor of survival in NSCLC, highlights metformin-modulated adipose effects, and elucidates molecular links to the obesity paradox, informing personalized prognosis beyond BMI.
Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes
Posted inNeurology news Oncology

Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes

An international cohort of 2,052 NSCLC patients with leptomeningeal disease shows rising prevalence and improved survival in the modern treatment era. CNS‑penetrant tyrosine kinase inhibitors and immune checkpoint inhibitors are key drivers of delayed onset and longer leptomeningeal survival.